Detalhe da pesquisa
1.
Phase 1 study of safety and tolerability of an oral contraceptive containing low-dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women.
J Viral Hepat
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654438
2.
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by ß-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
J Antimicrob Chemother
; 78(11): 2672-2682, 2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37700689
3.
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
J Viral Hepat
; 29(12): 1050-1061, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36036117
4.
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
Liver Int
; 42(6): 1278-1286, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220658
5.
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
J Viral Hepat
; 28(11): 1635-1642, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34448313
6.
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.
Hepatology
; 71(2): 456-462, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31254392
7.
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
Ann Hepatol
; 20: 100257, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949786
8.
Glecaprevir/pibrentasvir for 8â¯weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
J Hepatol
; 72(3): 441-449, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682879
9.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Hepatology
; 67(2): 505-513, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28865152
10.
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Antimicrob Agents Chemother
; 62(2)2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29180522
11.
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
J Med Virol
; 90(1): 109-119, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28842997
12.
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Antimicrob Agents Chemother
; 60(2): 1106-13, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26643326
13.
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
Hepatology
; 62(4): 1037-46, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26147154
14.
Boceprevir for previously treated chronic HCV genotype 1 infection.
N Engl J Med
; 364(13): 1207-17, 2011 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-21449784
15.
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Gastroenterology
; 145(5): 1035-1044.e5, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23924660
16.
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Hepatology
; 57(3): 974-84, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23081753
17.
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Liver Int
; 34(5): 707-19, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24118703
18.
Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
J Clin Gastroenterol
; 48(5): 435-43, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24177376
19.
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
J Hepatol
; 58(3): 452-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23159770
20.
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
J Hepatol
; 58(3): 479-87, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23183529